X0306 4 2022-01-13 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856369 Gibson Christopher C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 1 1 0 0 Chief Executive Officer Class A Common Stock 2022-01-13 4 C 0 87000 0.00 A 110470 D Class A Common Stock 2022-01-13 4 S 0 78206 14.2571 D 32264 D Class A Common Stock 2022-01-13 4 S 0 8794 14.9619 D 23470 D Class A Common Stock 2022-01-14 4 C 0 254000 0.00 A 277470 D Class A Common Stock 2022-01-14 4 S 0 254000 13.5654 D 23470 D Class B Common Stock 0.00 2021-12-28 5 G 0 E 75000 0.00 D Class A Common Stock 75000 8119342 D Class B Common Stock 0.00 2022-01-13 4 C 0 87000 0.00 D Class A Common Stock 87000 8032342 D Class B Common Stock 0.00 2022-01-14 4 C 0 254000 0.00 D Class A Common Stock 254000 7778342 D Stock Option (Right to Buy) 2.47 2030-12-30 Class A Common Stock 1471354 1471354 D Class B Common Stock 0.00 Class A Common Stock 550000 550000 I by LAHWRAN-3 LLC Class B Common Stock 0.00 Class A Common Stock 550000 550000 I by LAHWRAN-4 LLC Class B Common Stock 0.00 Class A Common Stock 146875 146875 I by Gibson Family Trust Represents the conversion of Class B Common Stock into Class A Common Stock. Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. This transaction was executed in multiple trades at prices ranging from $13.80 to $14.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $14.80 to $15.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $13.09 to $14.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. /s/ Nathan Hatfield, attorney-in-fact 2022-01-14